Shares of Akebia Therapeutics Inc. (AKBA) jumped over 28% in after-hours trading on Tuesday, following an expanded collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. to develop and commercialize Vadadustat in Europe, China and other territories.
from RTT - Biotech http://ift.tt/2p2Ozv8
via IFTTT
No comments:
Post a Comment